Slide 1: AMPLIFY-7P Phase 2 Immunogenicity Data
September 2025 AMPLIFY-7P Phase 2 Immunogenicity Data Nasdaq: ELTX Exhibit 99.2
Slide 2: Disclaimers: No Representation or Warranty
Disclaimers No Representation or Warranty We do not make and hereby expressly disclaim any representation or warranty, express or implied, as to the reasonableness of the assumptions made in the Presentation or the accuracy or completeness or the information contained in or incorporated by reference
Slide 3: Disclaimers: Forward-Looking Statements
Disclaimers Forward-Looking Statements This presentation contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, kno
Slide 4: Key take-home points
Key take-home points: Phase 2: mKRAS-specific T cell Responses to ELI-002 were Consistent with Observations in Phase 1 Trials that Correlated with Clinical Activity1 Phase 1: mKRAS-specific T cell Responses above ~9x over baseline correlated with clinical activity in two previous Phase 1 trials of E
Slide 5: ELI-002 7P Generated Robust T-Cell Responses In Ongoing Phase 2
Phase 1, 2 ELI-002 2P/7P ELI-002 7P Generated Robust T-Cell Responses In Ongoing Phase 2 Response Consistent with Observations in Phase 1 Trials of ELI-002 that Correlated with Clinical Activity ELI-002 7P data based on n = 90 evaluable Patients (4.9 mg AMP-Peptides) Robust expansion of mKRAS-specif
Slide 6: mKRAS: Expanded Antigen Coverage
mKRAS: Expanded Antigen Coverage G12D / R / V / C / A / S / G13D CLINICAL STUDY OVERVIEW: NCT05726864 Includes: mKRAS G12D/R/V/C/A/S/G13D Up front resectable Stage I, II or III disease (PDAC) Complete R0/R1 resection Radiographic NED status within 6 months following completion of locoregional treatm
Slide 7: Comparison of ELI-002 2P and 7P trial designs
Phase 1 ELI-002 2P Phase 1 ELI-002 7P Phase 2 ELI-002 7P # of patients (n) 25 14 144 Component dose optimized Adjuvant AMP-CpG Antigen AMP-Peptides 7P Uses recommended Phase 2 Dose of 10.0 mg adjuvant, 4.9 mg antigens KRAS mutations eligible G12D, G12R G12D, G12V, G12R, G12C, G12A, G12S, G13D G12D,
Slide 8: ELI-002 2P Phase 1 mKRAS T cell response
ELI-002 2P (Nature Medicine) Phase 1 (n=25) Patients MRD+ only mKRAS T Cell Response T cell Response Rate (%, n) 84% (21/25) Median Fold Change1 (range) 16.4x (2.1x to 423x) Threshold Above Which Clinical Activity was Correlated (% of Patients Above Threshold) 9.17x (68%) 12.75x (56%) CD4 + CD8 T ce
Slide 9: Final Analysis of ELI-002 2P Phase 1: T cell Response Correlated To Clinical Activity
Pant et al. Nature Medicine. 2024 Wainberg, et al. Nature Medicine. 2025 Data Cut-off 6 Sept 2023 24 Sept 2024 Median Follow-up 8.5 months 19.7 months Historic MRD+ PDAC Median RFS (n=25) 16.33 months 16.33 months 5.0 – 6.4 months Median OS (n=25) 16.33 months 28.94 months 17 months mKRAS T Cell Res
Slide 10: Phase 1 and Phase 2 immunogenicity comparison
ELI-002 2P (Nature Medicine) ELI-002 7P (4.9 mg) ELI-002 7P All (1.4 mg & 4.9 mg) ELI-002 7P (4.9 mg) Phase 1 (n=25) Phase 1 (n=7) Phase 1 (n=12) Phase 2 (n=90) Patients MRD+ only MRD+ only MRD+ only MRD+ & MRD- mKRAS T Cell Response T cell Response Rate (%, n) 84% (21/25) 100% (7/7) 100% (12/12) 99
Slide 11: Executive Summary: Key Takeaways from Phase 2 Immunogenicity Data
Executive Summary: Key Takeaways from Phase 2 Immunogenicity Data T cell Responses from Phase 2 were consistent across numerous metrics of magnitude and functional quality with responses observed in previous Phase 1 studies of ELI-002 2P and ELI-002 7P where T cell Response was correlated to clinica
Slide 12: AMPLIFY-7P Phase 2 Immunogenicity Data
September 2025 AMPLIFY-7P Phase 2 Immunogenicity Data Nasdaq: ELTX